Stay updated on Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial
Sign up to get notified when there's something new on the Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial page.

Latest updates to the Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoChange DetectedA recruitment-closed banner is now displayed on the page. New help sections (How to Read a Study Record, Common Questions, How to Join a Study) are added, and a formatting change updates 'Intervention / Treatment' to 'Intervention/Treatment' along with a revision stamp to v3.6.0.SummaryDifference0.4%

- Check18 days agoChange DetectedPage revision tag updated from v3.5.4 to v3.5.5, indicating a maintenance/patch-level update to the page. This change does not alter the visible content or behavior of the page.SummaryDifference0.1%

- Check39 days agoChange DetectedThe page shows a new revision tag, v3.5.4, replacing the previous v3.5.3, indicating a small update to the document version. The change affects metadata only and does not modify study details or results.SummaryDifference0.1%

- Check60 days agoChange DetectedThe page’s site “Revision” indicator was updated from v3.5.2 to v3.5.3.SummaryDifference0.1%

- Check67 days agoChange DetectedRevision upgraded from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check96 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0; no substantive study information changes are evident.SummaryDifference0.1%

Stay in the know with updates to Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial page.